Abstract:【Objective】 To investigate the correlation between the expression levels of long non-coding RNA(LncRNA) SNHG16 and SNHG19 in breast cancer tissues and the pathological characteristics as well as prognosis of patients.【Methods】 The expression levels of LncRNA SNHG16 and SNHG19 were detected in breast cancer tissues and adjacent normal tissues from 98 patients with breast cancer. Their associations with pathological features and prognosis were analyzed.【Results】 The expression levels of LncRNA SNHG16 and SNHG19 in breast cancer tissues were significantly higher than those in adjacent normal tissues (both P<0.05). Patients with high expression levels of LncRNA SNHG16 and SNHG19 had significantly lower 3-year survival rates than those with low expression (both P<0.05). The expression levels of LncRNA SNHG16 and SNHG19 were significantly correlated with patient age, estrogen receptor (ER) status, progesterone receptor (PR) status, and lymph node metastasis (all P<0.05). Additionally,LncRNA SNHG19 expression was significantly associated with TNM staging (P<0.05). Advanced age, ER negativity, PR negativity, TNM stage Ⅲ-Ⅳ, lymph node metastasis, high LncRNA SNHG16 expression, and high LncRNA SNHG19 expression were all risk factors affecting patient prognosis (all P<0.05).【Conclusion】 LncRNA SNHG16 and SNHG19 may act as important biomarkers for poor prognosis in breast cancer. They can provide references for diagnosis, prognostic evaluation, and treatment of breast cancer.
刘素娟, 周小芬, 王大鹏. 乳腺癌组织中长非编码RNA SNHG16和SNHG19表达及其与病理特征、预后的关系[J]. 医学临床研究, 2025, 42(12): 2039-2041.
LIU Sujuan, ZHOU Xiaofen, WANG Dapeng. Relationship of the Expression of Long Non-Coding RNAs SNHG16 and SNHG19 in Breast Cancer Tissues with Pathological Features and Prognosis. JOURNAL OF CLINICAL RESEARCH, 2025, 42(12): 2039-2041.
[1] 白紫合. Her2低表达晚期乳腺癌药物治疗的研究进展[J].河北医科大学学报,2023,44(7):860-865.
[2] 独晓燕,马秀芬,周海存,等. 血清CTC联合临床特征对乳腺癌新辅助治疗效果的预测价值[J].中国现代医学杂志,2023,33(5):1-8.
[3] 杨良权,于淼,姜茜,等. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J].基础医学与临床,2023,43(1):95-101.
[4] GONG C Y, TANG R, NAN W, et al. Role of SNHG16 in human cancer[J].Clin Chim Acta,2020, 4(503): 175-180.
[5] 吕凌云,彭宇,鲁亚琴,等. 卵泡抑素相关基因3对肿瘤相关巨噬细胞在乳腺癌增殖、迁移和侵袭中的机制研究[J].海军医学杂志,2022,43(7):697-703.
[6] 王婷婷,赵一涵. CCR8+Tregs:三阴性乳腺癌潜在治疗靶点[J].河北医科大学学报,2022,43(10):1220-1223.
[7] 蒋树云,马德寿,马志军. R-spondins与乳腺癌的相关性研究进展[J].中国现代医学杂志,2023,33(5):43-49.
[8] ZHONG Q, QIU R. Mechanism of lncRNA SNHG19 miR-299-5p MAPK6 signaling axis promoting metastasis of non-small cell lung cancer cells[J].Oncol Transl Med,2022, 8(5): 247-258.
[9] 杨丰帅,邱东达,杨运泉,等. LncRNA SNHG16靶向调控miR-516a-5p对结直肠癌细胞增殖、侵袭和迁移能力的影响[J].实用医学杂志,2023,39(20):2591-2596.
[10] 刘景云,杨斌,熊丽,等. 上皮性卵巢癌患者血清miR-302b-3p、lncRNA SNHG16水平变化及其临床意义[J].山东医药,2022,62(16):9-13.
[11] 李萍,刁玉佩,宋春霞. 长链非编码RNA SNHG16通过微小RNA-455-3p/Nocth2对鼻咽癌细胞增殖、凋亡和周期的影响[J].中华实验外科杂志,2022,39(10):1964-1967.
[12] LI Y P, JIN L, WANG F, et al. Epigenetic axis of SNHG19/miR-137/TNFAIP1 modulates amyloid beta peptide 25-35-induced SH-SY5Y cytotoxicity[J].Epigenomics,2022,14(4):187.
[13] 何小汶,谭韵. 长链非编码RNA SNHG16靶向微小RNA-7-5p对喉癌细胞增殖、迁移、侵袭的影响[J].安徽医药,2021,25(3):456-461.